All In Biotech

Drug Trial Radar · NCT07215234

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Oct 9, 2025

Primary completion

Oct 13, 2027

Study completion Jul 22, 2032

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase. The treatment is a one-time intravitreal injection of SAR446597 (or sham as applicable in Part II).

Conditions

  • Geographic Atrophy

Interventions

  • SAR446597Drug

    Intravitreal injection

  • Sham ComparatorDrug

    Sham injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs)Time frame: Day 1 to Week 104
  2. Incidence and severity of ocular and non-ocular treatment-emergent serious adverse events (TESAEs)Time frame: Day 1 to Week 104

Locations

35 sites in 3 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants - Peoria- Site Number : 8400011

    Peoria, Arizona · Recruiting

  • Retina Macula Institute of Arizona- Site Number : 8400028

    Scottsdale, Arizona · Recruiting

  • Retina-Vitreous Associates Medical Group - Beverly Hills- Site Number : 8400033

    Beverly Hills, California · Recruiting

  • The Retina Partners- Site Number : 8400040

    Encino, California · Recruiting

  • California Retina Consultants - Oxnard - North Ventura Road- Site Number : 8400014

    Oxnard, California · Recruiting

  • Retinal Consultants - Sacramento - Parkcenter Drive- Site Number : 8400054

    Sacramento, California · Recruiting

  • Macula Retina Vitreous Center - Torrance- Site Number : 8400053

    Torrance, California · Recruiting

  • Bay Area Retina Associates - Walnut Creek - Lennon Lane- Site Number : 8400039

    Walnut Creek, California · Recruiting

  • Vitreo Retinal Associates - Gainesville- Site Number : 8400004

    Gainesville, Florida · Recruiting

  • Retina Vitreous Associates of Florida - St. Petersburg- Site Number : 8400002

    St. Petersburg, Florida · Recruiting

  • East Florida Eye Institute- Site Number : 8400038

    Stuart, Florida · Recruiting

  • Southeast Retina Center- Site Number : 8400044

    Augusta, Georgia · Recruiting

  • University Retina - Lemont- Site Number : 8400005

    Lemont, Illinois · Recruiting

  • The Retina Group of Washington - Chevy Chase- Site Number : 8400009

    Chevy Chase, Maryland · Recruiting

  • Cumberland Valley Retina Consultants - Hagerstown- Site Number : 8400003

    Hagerstown, Maryland · Recruiting

  • Retina Specialist- Site Number : 8400055

    Towson, Maryland · Recruiting

  • Sierra Eye Associates- Site Number : 8400021

    Reno, Nevada · Recruiting

  • North Carolina (Nc) Retina Associates - Wake Forest Office- Site Number : 8400059

    Wake Forest, North Carolina · Recruiting

  • Oregon Retina- Site Number : 8400017

    Eugene, Oregon · Recruiting

  • Mid Atlantic Retina - Bethlehem- Site Number : 8400031

    Bethlehem, Pennsylvania · Recruiting

  • Erie Retina Research- Site Number : 8400035

    Erie, Pennsylvania · Recruiting

  • Charleston Neuroscience Institute - Ladson- Site Number : 8400016

    Ladson, South Carolina · Recruiting

  • Charleston Neuroscience Institute - Ladson- Site Number : 8400046

    Ladson, South Carolina · Recruiting

  • Texas Retina Associates - Arlington- Site Number : 8400056

    Arlington, Texas · Recruiting

  • Retina Consultants of Austin- Site Number : 8400015

    Austin, Texas · Recruiting

  • Austin Clinical Research - Austin - Anderson Mill Road- Site Number : 8400007

    Austin, Texas · Recruiting

  • Retina Consultants of Texas - Bellaire- Site Number : 8400019

    Bellaire, Texas · Recruiting

  • Retina Foundation of the Southwest- Site Number : 8400001

    Dallas, Texas · Recruiting

  • Texas Retina Associates - Dallas- Site Number : 8400006

    Dallas, Texas · Recruiting

  • Retinal Consultants of Texas - San Antonio- Site Number : 8400012

    San Antonio, Texas · Recruiting

  • Retina Center of Texas (RCT) - Southlake- Site Number : 8400048

    Southlake, Texas · Recruiting

  • Investigational Site Number : 0360003

    Sydney, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360002

    Adelaide, South Australia, Australia · Recruiting

  • Investigational Site Number : 0360001

    East Melbourne, Victoria, Australia · Recruiting

  • Investigational Site Number : 8260001

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.